Pharmacological protection of the myocardium with reamberin in coronary artery bypass grafting in patients with postinfarction angina
- 作者: Sidorenko G.I.1, Gelis L.G.1, Medvedeva E.A.1, Ostrovskiy Y.P.1, Lazareva I.V.1, Sevruk T.V.1, Shibeko N.A.1, Petrov Y.P.1, Sidorenko GI2, Gelis LG2, Medvedeva EA2, Ostrovsky Y.P2, Lazareva IV2, Sevruk TV2, Shibeko NA2, Petrov Y.P2
-
隶属关系:
- Republican Research and Practical Center "Cardiology", Minsk, Republic of Belarus
- 期: 卷 83, 编号 9 (2011)
- 页面: 35-40
- 栏目: Editorial
- ##submission.dateSubmitted##: 10.04.2020
- ##submission.datePublished##: 15.09.2011
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30909
- ID: 30909
如何引用文章
全文:
详细
Material and methods. A total of 45 patients with Q-positive MI complicated with postinfarction angina pectoris entered the trial. The study group consisted of 20 (44.4%) patients given 200-400 ml injections of 1.5% reamberin solution for 3 days before coronary artery bypass grafting (CABG) and 3-5 days after it. The control group consisted of 25 (55.6%) patients given basic therapy without cardioprotection. ECTG-60, echocardiography, CM-ECG, laboratory tests were made before CABG. CABG was made in conditions of artificial blood circulation in all the patients.
Results. Clinical stabilization was observed after direct myocardial revascularization in hospitalized 25 (100%) patients of the study group and 22 (88%) patients of the control group. Early postoperative acute cardiac failure (ACF) developed in 3 (12%) patients from the study group and 9 (36%) from the control group (p = 0.04), arrhythmia occurred in 2(8%) and 8(32%) patients, respectively (p = 0.03). Two (8%) control patients died in early postoperative period from acute cardiac failure. Perioperative MI occurred in 2(8%) control patients. After 12 months of the follow-up, patients of the study group had no recurrent angina pectoris, while among the controls 4(16%) patients had recurrent angina of FC III. After surgical intervention at discharge and 12 months after treatment patients of both groups improved systolic and diastolic functions of the left ventricle. Normalization of the diastolic function was registered in 80% patients of the study group (p < 0.001) and in 44% from the control group (p < 0.001) after 1 year follow-up.
Conclusion. Reamberin reduces the number of postoperative complications, ischemic damage to the myocardium, significantly improves systolic and diastolic functions of the left ventricle.
作者简介
Georgiy Sidorenko
Lyudmila Gelis
Elena Medvedeva
Email: elena-samonina@yandex.ru
Yuriy Ostrovskiy
Irina Lazareva
Tat'yana Sevruk
Natal'ya Shibeko
Yuriy Petrov
G Sidorenko
Republican Research and Practical Center "Cardiology", Minsk, Republic of BelarusRepublican Research and Practical Center "Cardiology", Minsk, Republic of Belarus
L Gelis
Republican Research and Practical Center "Cardiology", Minsk, Republic of BelarusRepublican Research and Practical Center "Cardiology", Minsk, Republic of Belarus
E Medvedeva
Republican Research and Practical Center "Cardiology", Minsk, Republic of BelarusRepublican Research and Practical Center "Cardiology", Minsk, Republic of Belarus
Yu Ostrovsky
Republican Research and Practical Center "Cardiology", Minsk, Republic of BelarusRepublican Research and Practical Center "Cardiology", Minsk, Republic of Belarus
I Lazareva
Republican Research and Practical Center "Cardiology", Minsk, Republic of BelarusRepublican Research and Practical Center "Cardiology", Minsk, Republic of Belarus
T Sevruk
Republican Research and Practical Center "Cardiology", Minsk, Republic of BelarusRepublican Research and Practical Center "Cardiology", Minsk, Republic of Belarus
N Shibeko
Republican Research and Practical Center "Cardiology", Minsk, Republic of BelarusRepublican Research and Practical Center "Cardiology", Minsk, Republic of Belarus
Yu Petrov
Republican Research and Practical Center "Cardiology", Minsk, Republic of BelarusRepublican Research and Practical Center "Cardiology", Minsk, Republic of Belarus
参考
- Бокерия Л. А., Маликов В. Е., Сигаев И. Ю. и др. Системы энергетического обеспечения, ПОЛ и лизосомальных ферментов при трансмиокардиальной лазерной реваскуляризации и ее сочетании с аортокоронарным шунтированием. Бюл. экспер. биол. 2002; прил. 2: 40-43.
- Мазина Н. К., Мазин П. В., Хазанов В. А. Некоторые теоретические и прикладные аспекты системного действия регуляторов энергетического обмена. В кн.: Регуляторы энергетического обмена. Клинико-фармакологические аспекты. Матер. V Всероссийского симпозиума. XIII Российский нац. конгресс "Человек и лекарство". М.; Томск, 2006: 93-101.
- Маликов В. Е., Сукаян Г. В., Юситов А. С. Способы кардиопротекции при хирургической реваскуляризации миокарда. М.: Изд-во НЦССХ им. А. Н. Бакулева РАМН; 2005. 56.
- Пархоменко А. Н., Иркин О. И., Кожунов С. Н. Возможности фармакологической защиты миокарда при синдроме ишемии-реперфузии в эксперименте и клинической практике. Лiкi Украiни 2002; 7-8: 2-11.
- Сидоренко Г. И., Комиссарова С. М. и др. Опыт применения актопротектора реамберина в клинике кардиохирургии. Клин. фармакол. и тер. 2007; 3: 39-43.
- Шабалин А. В., Никитин Ю. П. Защита кардиомиоцита. Современное состояние и перспективы. Кардиология 1999; 78 (3): 4-10.
- Beller G. A. Diagnostic accuracy of thallium-201 myocardial perfusion imaging. Circulation 1991; 84 (3): 11-16.
- Charney R., Schwinger M. E., Chun J. et al. Dobutamin echocardiography and resting-redistribution Thallium-201 scintigraphy predicts recovery of hibernating myocardium after coronary revascularization. Am.Heart J. 1994; 128: 864- 869.
- Gibson R. S., Watson D. D., Taylor G. J. Prospective assessment of regional myocardial perfusion befor and after coronary evascularization surgery by quantitative thallium-201 scintigraphy. J. Am. Coll. Cardiol. 1983; 1: 804-815.
补充文件
![](/img/style/loading.gif)